{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T18:28:07Z","timestamp":1771698487006,"version":"3.50.1"},"reference-count":32,"publisher":"Baishideng Publishing Group Inc.","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2009]]},"DOI":"10.3748\/wjg.15.990","type":"journal-article","created":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T01:49:38Z","timestamp":1236044978000},"page":"990","source":"Crossref","is-referenced-by-count":38,"title":["Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis"],"prefix":"10.3748","volume":"15","author":[{"given":"Ri-Nan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000;14:1589-1594.","DOI":"10.1046\/j.1365-2036.2000.00884.x"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-1456.","DOI":"10.1016\/S0016-5085(97)70025-8"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adlis S, Fendrick AM, Jones R, Dent J, Bytzer P. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001;96:52-57.","DOI":"10.1111\/j.1572-0241.2001.03451.x"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992;51 Suppl 1:24-29.","DOI":"10.1159\/000200911"},{"key":"ref5","unstructured":"Orlando RC. The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposure. Am J Gastroenterol 1997;92:3S-5S; discussion 5S-7S."},{"key":"ref6","unstructured":"Johnston BT, Collins JS, McFarland RJ, Love AH. Are esophageal symptoms reflux-related? A study of different scoring systems in a cohort of patients with heartburn. Am J Gastroenterol 1994;89:497-502."},{"key":"ref7","unstructured":"Winters C Jr, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF 3rd, Johnson DA, Cruess DF, Cotelingam JD, Gurney MS. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-124."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996;38:649-654.","DOI":"10.1136\/gut.38.5.649"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Johansson KE, Ask P, Boeryd B, Fransson SG, Tibbling L. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986;21:837-847.","DOI":"10.3109\/00365528609011128"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992;33:118-124.","DOI":"10.1136\/gut.33.1.118"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Jansen JB, Van Oene JC. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. Aliment Pharmacol Ther 1999;13:1611-1620.","DOI":"10.1046\/j.1365-2036.1999.00656.x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Kawano S, Murata H, Tsuji S, Kubo M, Tatsuta M, Iishi H, Kanda T, Sato T, Yoshihara H, Masuda E. Randomized comparative study of omeprazole and famotidine in reflux esophagitis. J Gastroenterol Hepatol 2002;17:955-959.","DOI":"10.1046\/j.1440-1746.2002.02785.x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997;272:22438-22446.","DOI":"10.1074\/jbc.272.36.22438"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998;12:1079-1089.","DOI":"10.1046\/j.1365-2036.1998.00418.x"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999;13 Suppl 3:3-10.","DOI":"10.1046\/j.1365-2036.1999.00019.x"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Gardner JD, Perdomo C, Sloan S, Hahne WF, Barth JA, Rodriguez-Stanley S, Robinson M. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther 2002;16:455-464.","DOI":"10.1046\/j.1365-2036.2002.01158.x"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002;16:1811-1817.","DOI":"10.1046\/j.1365-2036.2002.01348.x"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Dimenas E. Methodological aspects of evaluation of Quality of Life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 1993;199:18-21.","DOI":"10.3109\/00365529309098350"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996;221:8-13.","DOI":"10.3109\/00365529609095544"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-180.","DOI":"10.1136\/gut.45.2.172"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Ghillebert G, Demeyere AM, Janssens J, Vantrappen G. How well can quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease? Dig Dis Sci 1995;40:1317-1324.","DOI":"10.1007\/BF02065545"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J. Transient lower esophageal sphincter relaxation. Gastroenterology 1995;109:601-610.","DOI":"10.1016\/0016-5085(95)90351-8"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997;17:22-37.","DOI":"10.1002\/j.1875-9114.1997.tb03675.x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004;60:531-539.","DOI":"10.1007\/s00228-004-0804-6"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Rohss K, Wilder-Smith C, Naucler E, Jansson L. Esomeprazole 20mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Investig 2004;24:1-7.","DOI":"10.2165\/00044011-200424010-00001"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastro-esophageal reflux disease. Dig Dis Sci 2002;47:954-958.","DOI":"10.1023\/A:1015009300955"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Miner P Jr, Katz PO, Chen Y, Sostek M. Reanalysis of intragastric pH results based on updated correction factors for Slimline and Zinetics 24 single-use pH catheters. Am J Gastroenterol 2006;101:404-405; author reply 405-406.","DOI":"10.1111\/j.1572-0241.2006.00401_3.x"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998;33:15-20.","DOI":"10.1080\/00365529850166149"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther 2000;14:389-396.","DOI":"10.1046\/j.1365-2036.2000.00733.x"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Meier JH, McNally PR, Punja M, Freeman SR, Sudduth RH, Stocker N, Perry M, Spaulding HS. Does omeprazole (Prilosec) improve respiratory function in asthmatics with gastroesophageal reflux? A double-blind, placebo-controlled crossover study. Dig Dis Sci 1994;39:2127-2133.","DOI":"10.1007\/BF02090360"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Hanson DG, Kamel PL, Kahrilas PJ. Outcomes of antireflux therapy for the treatment of chronic laryngitis. Ann Otol Rhinol Laryngol 1995;104:550-555.","DOI":"10.1177\/000348949510400709"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999;117:11-16.","DOI":"10.1016\/S0016-5085(99)70544-5"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v15\/i8\/990.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:57:47Z","timestamp":1710118667000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v15\/i8\/990.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.15.990","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2009]]}}}